Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MEF2D Fusions Drive Oncogenic Pre-BCR Signaling in B-ALL.
Sadras T, Müschen M. Sadras T, et al. Blood Cancer Discov. 2020 Jun 22;1(1):18-20. doi: 10.1158/2643-3249.BCD-20-0078. eCollection 2020 Jul. Blood Cancer Discov. 2020. PMID: 34661138 Free PMC article.
Unusual PDGFRB fusion reveals novel mechanism of kinase activation in Ph-like B-ALL.
Sadras T, Jalud FB, Kosasih HJ, Horne CR, Brown LM, El-Kamand S, de Bock CE, McAloney L, Ng AP, Davidson NM, Ludlow LEA, Oshlack A, Cowley MJ, Khaw SL, Murphy JM, Ekert PG. Sadras T, et al. Leukemia. 2023 Apr;37(4):905-909. doi: 10.1038/s41375-023-01843-x. Epub 2023 Feb 21. Leukemia. 2023. PMID: 36810896 Free PMC article. No abstract available.
TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.
Nievergall E, Reynolds J, Kok CH, Watkins DB, Biondo M, Busfield SJ, Vairo G, Fuller K, Erber WN, Sadras T, Grose R, Yeung DT, Lopez AF, Hiwase DK, Hughes TP, White DL. Nievergall E, et al. Among authors: sadras t. Leukemia. 2016 Jun;30(6):1263-72. doi: 10.1038/leu.2016.34. Epub 2016 Feb 22. Leukemia. 2016. PMID: 26898188 Clinical Trial.
Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.
Sadras T, Heatley SL, Kok CH, Dang P, Galbraith KM, McClure BJ, Muskovic W, Venn NC, Moore S, Osborn M, Revesz T, Moore AS, Hughes TP, Yeung D, Sutton R, White DL. Sadras T, et al. Cancer Lett. 2017 Nov 1;408:92-101. doi: 10.1016/j.canlet.2017.08.034. Epub 2017 Sep 1. Cancer Lett. 2017. PMID: 28866095
21 results